Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Inv. presentation
|
|
PROGENICS PHARMACEUTICALS INC (PGNX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/22/2020 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 19, 2020 Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchang...",
"Fourth Amended and Restated Certificate of Incorporation of Progenics Pharmaceuticals, Inc., effective June 19, 2020",
"Amended and Restated Bylaws of Progenics, effective June 19, 2020",
"Lantheus Completes Merger with Progenics" |
|
| 06/17/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/16/2020 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 16, 2020 Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchang...",
"Progenics Stockholders Approve Merger with Lantheus , June 16, 2020 - Progenics Pharmaceuticals, Inc. , an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier today, Progenics' stockholders voted to approve its proposed merger with Lantheus Holdings, Inc. , a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, by adopting the previously announced Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 , by and among Progenics, Lantheus and Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus , pursuant to which Merger Sub will be merged with and into Progenics , with P..." |
|
| 06/11/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/08/2020 |
8-K
| Other Events |
| 05/28/2020 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant |
| 05/18/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/07/2020 |
8-K
| Quarterly results |
| 04/14/2020 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 14, 2020 Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchan...",
"Velan Capital Agrees to Support Merger of Lantheus and Progenics NORTH BILLERICA, Mass. and - April 14, 2020 - Lantheus Holdings, Inc. , parent company of Lantheus Medical Imaging, Inc. , a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. , an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has entered into a Support Agreement with Velan Capital in connection with the proposed merger of Lantheus and Progenics. Velan is a stockholder of both Progenics and Lantheus and the Support Agreement provides that Velan will vote all of its Progenics stock and Lantheus stock in favor of the proposed merger of ..." |
|
| 04/02/2020 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 2, 2020 Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchang...",
"Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger NORTH BILLERICA, MA - April 2, 2020 - Lantheus Holdings, Inc. , parent company of Lantheus Medical Imaging, Inc. , a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. , an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have decided to reschedule their respective special meetings of stockholders to vote on matters related to the proposed merger of Lantheus and Progenics from April 28, 2020, to June 16, 2020. The rescheduled Special Meetings will allow both companies the time necessary to respond to th..." |
|
| 04/01/2020 |
8-K
| Quarterly results |
| 03/16/2020 |
8-K
| Quarterly results |
| 03/13/2020 |
8-K
| Quarterly results |
| 03/04/2020 |
8-K
| Quarterly results |
| 02/20/2020 |
8-K
| Quarterly results |
| 02/20/2020 |
8-K
| Quarterly results |
| 01/21/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 12/23/2019 |
8-K
| Quarterly results |
| 12/19/2019 |
8-K
| Quarterly results |
| 11/21/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/15/2019 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 11/07/2019 |
8-K
| Quarterly results |
| 11/01/2019 |
8-K
| Quarterly results |
| 10/29/2019 |
8-K
| Investor presentation |
| 10/23/2019 |
8-K
| Quarterly results |
| 10/21/2019 |
8-K
| Quarterly results |
| 10/18/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/02/2019 |
8-K
| Quarterly results |
| 08/09/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results |
| 08/06/2019 |
8-K
| Quarterly results |
| 08/05/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 07/18/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
|
|
|